Mireille Centlivre

Founder at Linkinvax SA

Commercial Services

Profile

Mireille Centlivre is the founder of Linkinvax SA, where she currently holds the title of Chief Research & Development Officer.
The company was founded in 2020.

Mireille Centlivre active positions

Companies	Position	Start
Linkinvax SA Linkinvax SA Miscellaneous Commercial ServicesCommercial Services Linkinvax SA is a French company founded in 2020 by Remi Gaston-Dreyfus, Yves Lévy, André-Jacques Auberton-Hervé, Laurent Hanot, and Mireille Centlivre. The company is based in Paris, France. Linkinvax is developing an innovative protein-based vaccine platform that can accelerate the availability of vaccines by leveraging the research conducted at the Vaccine Research Institute (VRI). The platform is DC targeting-based and can adapt to changes and mutations in the target pathogens. Linkinvax aims to revolutionize vaccine development, particularly for new viruses like Chlamydia and COVID-19. The company is led by André-Jacques Auberton-Hervé, who has been the CEO since 2020.	Founder	31/12/2019

All active positions of Mireille Centlivre

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Mireille Centlivre's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Linkinvax SA Linkinvax SA Miscellaneous Commercial ServicesCommercial Services Linkinvax SA is a French company founded in 2020 by Remi Gaston-Dreyfus, Yves Lévy, André-Jacques Auberton-Hervé, Laurent Hanot, and Mireille Centlivre. The company is based in Paris, France. Linkinvax is developing an innovative protein-based vaccine platform that can accelerate the availability of vaccines by leveraging the research conducted at the Vaccine Research Institute (VRI). The platform is DC targeting-based and can adapt to changes and mutations in the target pathogens. Linkinvax aims to revolutionize vaccine development, particularly for new viruses like Chlamydia and COVID-19. The company is led by André-Jacques Auberton-Hervé, who has been the CEO since 2020.	Commercial Services